21. Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial. Issue 6 (27th November 2020) Authors: Albiges, Laurence; Tannir, Nizar M; Burotto, Mauricio; McDermott, David; Plimack, Elizabeth R; Barthélémy, Philippe; Porta, Camillo; Powles, Thomas; Donskov, Frede; George, Saby; Kollmannsberger, Christian K; Gurney, Howard; Grimm, Marc-Oliver; Tomita, Yoshihiko; Castellano, Daniel; Rini, Brian I... Journal: ESMO open Issue: Volume 5:Issue 6(2020) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
22. Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial. Issue 6 (27th November 2020) Authors: Albiges, Laurence; Tannir, Nizar M; Burotto, Mauricio; McDermott, David; Plimack, Elizabeth R; Barthélémy, Philippe; Porta, Camillo; Powles, Thomas; Donskov, Frede; George, Saby; Kollmannsberger, Christian K; Gurney, Howard; Grimm, Marc-Oliver; Tomita, Yoshihiko; Castellano, Daniel; Rini, Brian I... Journal: ESMO open Issue: Volume 5:Issue 6(2020) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
23. Nivolumab plus rucaparib for metastatic castration-resistant prostate cancer: results from the phase 2 CheckMate 9KD trial. Issue 8 (17th August 2022) Authors: Fizazi, Karim; Retz, Margitta; Petrylak, Daniel P; Goh, Jeffrey C; Perez-Gracia, Jose; Lacombe, Louis; Zschäbitz, Stefanie; Burotto, Mauricio; Mahammedi, Hakim; Gravis, Gwenaelle; Bastos, Diogo Assed; McCune, Steven L; Vázquez Limón, Juan Carlos; Kwan, Edmond M; Castellano, Daniel; Fléchon, Aude;... Journal: Journal for immunotherapy of cancer Issue: Volume 10:Issue 8(2022) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
24. Non-inferiority trials: why oncologists must remain wary. Issue 4 (April 2015) Authors: Burotto, Mauricio; Prasad, Vinay; Fojo, Tito Journal: Lancet oncology Issue: Volume 16:Issue 4(2015:Apr.) Page Start: 364 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
25. Non-inferiority trials: why oncologists must remain wary. Issue 4 (April 2015) Authors: Burotto, Mauricio; Prasad, Vinay; Fojo, Tito Journal: Lancet oncology Issue: Volume 16:Issue 4(2015:Apr.) Page Start: 364 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
26. Phase II Clinical Trial of Ixabepilone in Metastatic Cervical Carcinoma. (3rd June 2015) Authors: Burotto, Mauricio; Edgerly, Maureen; Poruchynsky, Marianne; Velarde, Margarita; Wilkerson, Julia; Kotz, Herb; Bates, Susan; Balasubramaniam, Sanjeeve; Fojo, Tito Journal: Oncologist Issue: Volume 20:Number 7(2015) Page Start: 725 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
27. Preference for the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer (PHranceSCa): A randomised, open-label phase II study. (July 2021) Authors: O'Shaughnessy, Joyce; Sousa, Susana; Cruz, Josefina; Fallowfield, Lesley; Auvinen, Päivi; Pulido, Catarina; Cvetanovic, Ana; Wilks, Sharon; Ribeiro, Leonor; Burotto, Mauricio; Klingbiel, Dirk; Messeri, Dimitri; Alexandrou, Ari; Trask, Peter; Fredriksson, Judy; Machackova, Zuzana; Stamatovic, Ljil... Journal: European journal of cancer Issue: Volume 152(2021) Page Start: 223 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
28. Primary Adrenal Insufficiency due to Immune Checkpoint Inhibitors: More Common than We Thought. (23rd November 2020) Authors: Salinas, Carlos; Samtani, Suraj; Burotto, Mauricio Journal: Oncologist Issue: Volume 26:Number 1(2021) Page Start: e191 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
29. Recommendations for detection, prioritization, and treatment of thoracic oncology patients during the COVID‐19 pandemic: the THOCOoP cooperative group. (September 2020) Authors: Arrieta, Oscar; Cardona, Andrés F.; Lara-Mejía, Luis; Heredia, David; Barrón, Feliciano; Zatarain-Barrón, Zyanya Lucia; Lozano, Francisco; de Lima, Vladmir Cordeiro; Maldonado, Federico; Corona-Cruz, Francisco; Ramos, Maritza; Cabrera, Luis; Martin, Claudio; Corrales, Luis; Cuello, Mauricio; Arro... Journal: Critical reviews in oncology/hematology Issue: Volume 153(2020) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
30. Results of a Dose‐Finding Phase 1b Study of Subcutaneous Atezolizumab in Patients With Locally Advanced or Metastatic Non–Small Cell Lung Cancer. Issue 10 (31st March 2021) Authors: Felip, Enriqueta; Burotto, Mauricio; Zvirbule, Zanete; Herraez‐Baranda, Luis A.; Chanu, Pascal; Kshirsagar, Smita; Maiya, Vidya; Chan, Phyllis; Pozzi, Emanuela; Marchand, Mathilde; Monchalin, Marion; Tanaka, Kunihiko; Tosti, Nadia; Wang, Bei; Restuccia, Eleonora Journal: Clinical pharmacology in drug development Issue: Volume 10:Issue 10(2021) Page Start: 1142 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗